Scopus BioPharma Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Scopus BioPharma Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2022.
  • Scopus BioPharma Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2023 was -$2.62M, a 21.2% increase year-over-year.
  • Scopus BioPharma Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2023 was -$8.7M, a 45.3% increase year-over-year.
  • Scopus BioPharma Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$11.6M, a 56.9% increase from 2021.
  • Scopus BioPharma Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$27M, a 148% decline from 2020.
  • Scopus BioPharma Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$10.9M, a 304% decline from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$11.6M +$15.3M +56.9% Jan 1, 2022 Dec 31, 2022 10-K 2023-04-14
2021 -$27M -$16.1M -148% Jan 1, 2021 Dec 31, 2021 10-K 2023-04-14
2020 -$10.9M -$8.17M -304% Jan 1, 2020 Dec 31, 2020 10-K 2022-04-15
2019 -$2.69M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.